Ubrogepant: A potential new drug in treating migraine

0
94

Presented to you by Meganox

All eyes are on the new oral pill “ubrogepant” after a large-scale clinical trial suggested that it can treat migraine faster and safer than other medications.

Twenty percent of the participants reported to be pain-free after two hours.

Migraine by the figures. An infographic about migraine across the globe. | Composed by Richard D. Meriveles
Migraine by the figures. An infographic about migraine across the globe. | Composed by Richard D. Meriveles

Neurology Reviews reported Joel Trugman, MD, Director of Clinical Development for Allergan, and colleagues “conducted phase III study to examine the efficacy, safety, and tolerability of ubrogepant, compared with placebo, for the acute treatment of a single migraine attack.”

More than 34 percent of the 1,672 participants said they felt relieved of the most disturbing symptoms of migraine which include light and noise sensitivity.

The medication is not yet approved by the US Food and Drug Administration.

Migraines are severe, repeated, and painful headaches that are often felt on one side of the head.

The pain it causes can last for hours or worse, for days.

Stress, depression, and anxiety are considered to be some of the emotional triggers that can cause migraine.

Hormonal changes especially for women during menstrual flow, alcohol and caffeine, medications including sleeping pills or contraceptive pills also trigger migraine.

Since migraine has no cure yet, treatments are made in order to prevent a full-blown attack, and to lessen the symptoms that may occur.

The American Migraine Foundation said one billion people experience migraine worldwide; one in every four households, one in every five women, one in every 16 men, and one in every 11 children.

It is always best to have a little lifestyle check in order to lessen possibilities of experiencing such disorder.

Get enough sleep, reduce stress, drinking water daily, and exercise regularly, to keep migraine away.

Leave a Reply